HFE Compound Heterozygosity (C282Y/H63D)

Your Genotype

You carry one copy of each major HFE variant:

This makes you a compound heterozygote, distinct from C282Y homozygotes who carry the highest risk.

flowchart TD
    GENO["C282Y/H63D Genotype"] --> CONS["Low-risk consensus"]
    GENO --> EMERGE["Emerging evidence"]

    CONS --> GUIDE["Guidelines: no family screening"]
    CONS --> STATS["3.5% penetrance in males"]

    EMERGE --> SUBSET["Subset loads iron"]
    EMERGE --> MODIFY["Genetic modifiers"]
    EMERGE --> PHENO["Phenotype matters more"]

    SUBSET --> DECISION{Clinical Decision}
    PHENO --> DECISION

    DECISION --> MONITOR["Monitor: TSAT + ferritin"]
    DECISION --> TREAT["Treat: phlebotomy"]
    DECISION --> IMAGE["Investigate: hepatic MRI"]

    GUIDE -.-> GAP["Genotype-Phenotype Gap"]
    SUBSET -.-> GAP
    GAP -.-> DECISION

    classDef consensus fill:#85c1e9,stroke:#2471a3,color:#0a1929
    classDef emerging fill:#f0b27a,stroke:#ca6f1e,color:#1a1000
    classDef decision fill:#85c1e9,stroke:#2471a3,color:#0a1929
    classDef gap fill:#b06272,stroke:#8a4252,color:#fff

    class GENO,CONS,GUIDE,STATS consensus
    class EMERGE,SUBSET,MODIFY,PHENO emerging
    class DECISION,MONITOR,TREAT,IMAGE decision
    class GAP gap

Population Prevalence

Clinical Penetrance — What the Research Shows

The "Low Risk" Consensus

The traditional view, reflected in your lab report, is that compound heterozygotes rarely develop clinical haemochromatosis:

"C282Y/H63D compound heterozygotes are at low risk of hemochromatosis-related morbidity" — Gurrin et al., Hepatology 2009; 50(1):94-101. PMC3763940

The Emerging Nuance

Recent research challenges the blanket "benign" label:

"C282Y/H63D Compound Heterozygosity Is a Low Penetrance Genotype for Iron Overload-related Disease" — Hasan et al., J Can Assoc Gastroenterol 2022;5(5):240-247. PMC9527664

Key finding: While penetrance is low overall, a subset of compound heterozygotes DO develop clinically significant iron overload, especially:

Haemochromatosis UK (2025): "Recent publications have argued that the H63D variant lacks diagnostic or clinical utility... However, this interpretation risks overlooking patients with clinically relevant iron overload."

Your Situation — The Phenotype Matters More Than Genotype

Your biochemistry tells a different story from the "low risk" label:

Per EASL Clinical Practice Guidelines on Haemochromatosis (2022):

In patients with high TSAT and elevated ferritin but non-C282Y homozygous genotypes, diagnosis requires hepatic iron overload on MRI or liver biopsy.

UK Biobank Data (2025-2026)

BMC Genomics (March 2026): "Unraveling genotype-phenotype relationships in hereditary hemochromatosis through integrated biobank data analysis" — Large-scale analysis showing HH genotype-phenotype associations are difficult to predict due to variable penetrance and expressivity.

Pilling et al., medRxiv 2025: Genetic and lifestyle modifiers affect penetrance in C282Y homozygotes. While focused on homozygotes, the principle that lifestyle/genetic modifiers affect penetrance applies to compound hets.

Additional Genetic Modifiers to Consider

Your iron loading despite "low risk" genotype may be influenced by:

  1. Other iron-regulatory gene variants: HAMP (hepcidin), HJV (hemojuvelin), TFR2 (transferrin receptor 2), SLC40A1 (ferroportin)
  2. TMPRSS6 variants: affect hepcidin regulation
  3. Modifier genes: matriptase-2, BMP pathway components
  4. Epigenetic factors: inflammation, metabolic status, diet

"Other causes of severe iron loading should also be investigated for possible other contributing iron overload genotypes" — from your lab report

The 10% Gap

Your report notes: "Approximately 10% of HFE-related HH patients would not have variants detected by our tests." This means rarer HFE variants or non-HFE iron genes could contribute.

Implications for You

  1. Your phenotype overrides your genotype — you ARE loading iron, regardless of the statistical rarity
  2. Monitoring is warranted despite guidelines not recommending family screening
  3. Consider: requesting hepatic iron MRI (T2*/FerriScan) to quantify actual organ iron
  4. Consider: genetic panel for additional iron-regulatory genes
  5. The compound het genotype may still affect brain iron homeostasis

Key References

  1. Gurrin LC et al. HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis-related morbidity. Hepatology. 2009;50(1):94-101. PMC3763940
  2. Hasan SM et al. C282Y/H63D compound heterozygosity is a low penetrance genotype for iron overload-related disease. J Can Assoc Gastroenterol. 2022;5(5):240-247. PMC9527664
  3. Fitzsimons EJ et al. Diagnosis and therapy of genetic haemochromatosis (review and 2017 update). Br J Haematol. 2018;181:293-303
  4. EASL Clinical Practice Guidelines on haemochromatosis. J Hepatol. 2022;77(2):479-502
  5. Lim DR et al. Clinical penetrance of hereditary hemochromatosis-related liver disease. Clin Transl Gastroenterol. 2020;11(11):e00249
  6. BMC Genomics. Unraveling genotype-phenotype relationships in hereditary hemochromatosis. March 2026
  7. Pilling LC et al. Genetic and lifestyle modifiers of haemochromatosis-related clinical outcomes. medRxiv. 2025
  8. Anderson GJ. Revisiting hemochromatosis: genetic vs. phenotypic manifestations. Ann Transl Med
  9. Toama W et al. Iron study is a weak indicator in symptomatic C282Y/H63D compound heterozygotes. 2015

Cross-References